At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 2 enrolled
Drug / intervention
nonavalent human papillomavirus vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Therapeutic Intralesional Nonavalent HPV Vaccine for Genital Condylomata in Adults: an Open Label Pilot Study
In Brief
A Phase 2 clinical trial evaluating nonavalent human papillomavirus vaccine for Human Papilloma Virus and 4 related conditions. Completed, enrolled 2 participants across 1 site.
Detailed Summary
This study will investigate whether injecting genital warts with small quantities of the Gardasil 9 vaccine has an effect on the warts.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Papilloma Virus, Warts, Warts, Genital, Condyloma, Condylomata Acuminata
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedOct 2021
Enrollment StartApr 2022
Primary CompletionJul 2024
TodayJul 2026
First PostedOct 21, 2021
Enrollment StartApr 15, 2022
Primary CompletionJul 1, 2024
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 4.7 years ago
Interventions
nonavalent human papillomavirus vaccinebiological
Intralesional injection of nonavalent human papillomavirus vaccine (Gardasil 9) at 0 and 4 weeks